TrialThe Lancet. Oncology2016

Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial.

Anas Younes et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.